Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Looks like Dawn is under pressure on several fronts

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Apr 29, 2021 4:36pm

144 Views

Post# 33095571

RE:Looks like Dawn is under pressure on several fronts

I have not had time to look into this but apparently another investor is frustrated by a company Dawn serves on the board of - https://www.businesswire.com/news/home/20210429006034/en/The-Sonic-Fund-II-L.P.-Comments-on-Adverum-Biotechnologies-Update-Regarding-INFINITY-Phase-2-Trial-of-ADVM-022.